Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 463

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms

Plate, Karl H., Breier, Georg, Weich, Herbert A., Mennel, Hans D., Risau, Werner·1994·International Journal of Cancer

Abstract

We have previously suggested that tumor angiogenesis in human gliomas is regulated by a paracrine mechanism involving vascular endothelial growth factor (VEGF) and flt‐I (VEGF‐receptor I). VEGF, an endothelial‐cell‐specific mitogen, is abundantly expressed in glioma cells which reside along necrotic areas, whereas fit‐I, a tyrosine‐kinase receptor for VEGF, is expressed in tumor endothelial cells, but not in endothelial cells in normal adult brain. Recently, a second tyrosine‐kinase receptor which binds VEGF with high affinity, designated KDR or flk‐I, has been described. We performed in situ hybridization for VEGF mRNA, flt‐I mRNA and KDR mRNA on serial sections of normal brain, low‐grade and high‐grade glioma specimens. We show that KDR mRNA is co‐expressed with flt‐I in vascular cells in glioblastoma but not in low‐grade glioma. Since flt‐I and KDR are not expressed in endothelial cells in the normal adult brain, the coordinate up‐regulation of 2 receptors for VEGF appears to be a critical event which controls tumor angiogenesis. Immunocytochemistry with a monoclonal anti‐VEGF antibody revealed significant amounts of VEGF protein in the same glioma cells that expressed VEGF mRNA. The largest amount of VEGF immunoreactivity, however, was detected on the vasculature of glioblastomas, the site where VEGF exerts its biological functions. These findings suggest that VEGF is produced and secreted by glioma cells and acts on tumor endothelial cells which express VEGF receptors. To further characterize VEGF‐producer cells in vivo, we investigated cellular proliferation, immunoreactivity to the p53 tumor‐suppressor gene product and epidermal‐growth‐factor‐receptor(EGFR) expression on serial sections by immunocytochemistry. VEGF‐producer cells did not show increased cellular proliferation, p53 immunoreactivity or EGFR immunoreactivity as compared with glioma cells which did not express VEGF. Our studies therefore do not demonstrate evidence for a growth advantage of VEGF‐producer cells in vivo or VEGF induction by p53 mutation or EGFR over‐expression. © 1994 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.2910590415

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Metadata

Authors
Plate, K. H., Breier, G., Weich, H. A., Mennel, H. D., & Risau, W.
Venue
International Journal of Cancer
Publisher
Wiley
Published
1994-11-15
Volume
59
Issue
4
Pages
520-529
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2053375897
Cited by
463
References
3
FWCI
6.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms. https://app.cochat.ai/papers/10.1002/ijc.2910590415
The paper
Plate, K. H., Breier, G., Weich, H. A., Mennel, H. D., & Risau, W. (1994). Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms. International Journal of Cancer. https://doi.org/10.1002/ijc.2910590415

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.